Imagine a tiny, smart plug for the heart that stops blood clots from traveling to the brain and causing strokes. It also comes with a miniature sensor that acts like a smoke alarm for heart failure, alerting doctors before a crisis happens. Instead of multiple surgeries, these tools work together in one simple procedure.
Chronic cardiovascular disease costs the EU €210 billion annually. Many high-risk patients cannot use current implants because they lack adaptability and safety, leading to preventable strokes and heart failure.
A modular implant platform consisting of Zenith (a left atrial appendage sealer for stroke prevention) and Halo (a miniature pressure sensor for heart failure monitoring).
If you are a cardiac implant developer dealing with rigid, single-purpose devices — this project developed a modular platform that combines stroke prevention and real-time monitoring. This allows for treating complex patients in a single minimally invasive procedure.
If you are a private cardiology clinic dealing with high costs of chronic heart disease — this project developed the Zenith and Halo systems. These tools reduce the need for long-term anticoagulant medication and enable early detection of heart failure.
If you are a medical insurance provider dealing with the €210 billion annual cost of cardiovascular disease in Europe — this project developed a system to manage the most expensive patients more effectively. It aims to lower the cost per patient through a single, fast procedure.
Based on available project data, specific unit pricing is not provided, but the project aims to lower the overall cost per patient for the most expensive chronic cardiac cases.
The Zenith device has moved from laboratory prototype to a clinically validated system with successful human implantation, indicating it is moving toward industrial scale.
Based on available project data, specific patent numbers or licensing terms are not listed, though the project was led by AuriGen Medical Limited as an SME.
The project completed a First-in-Human clinical study with ten patients, achieving 100% of safety and performance endpoints.
The project period ran from 2023-06-01 to 2025-06-30, focusing on validation and pre-clinical milestones.
The project is led by a single SME, AuriGen Medical Limited, based in Ireland. With a 100% industry ratio and no university or research partners, the consortium is streamlined for commercialization and rapid translation from prototype to clinical validation.
Contact AuriGen Medical Limited in Ireland
Contact us to explore licensing opportunities for the Zenith and Halo cardiac platform.
